Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer

Reference

• Griffths CL, Olin JL. Triple Negative Breast Cancer: a brief review of its characteristics and treatment options. J Pharm Pract 2012; 25:319-23; PMID:22551559; http://dx.doi.org/10.1177/0897190012442062
   PubMedGoogle Scholar
• Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol 2012; 23:2223-34; PMID:22517820; http://dx.doi.org/10.1093/annonc/mds067
   PubMed Web of Science ®Google Scholar
• Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006; 1:119-50; PMID:18039110; http://dx.doi.org/10.1146/annurev.pathol.1.110304.100224
   PubMed Web of Science ®Google Scholar
• Kim JB, Stein R, O'Hare MJ. Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol 2005; 26:173-85; PMID:16006771
   PubMed Web of Science ®Google Scholar
• Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002; 296:1046-9; PMID:12004111; http://dx.doi.org/10.1126/science.1067431
   PubMed Web of Science ®Google Scholar
• Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004; 4:839-49; PMID:15516957
   PubMed Web of Science ®Google Scholar
• Lisanti MP, Martinez-Outschoorn U, Sotgia F. Oncogenes induce the cancer-associated fibroblast phenotype. Cell Cycle 2013; 12:2723-32; PMID:23860382; http://dx.doi.org/10.4161/cc.25695
   PubMed Web of Science ®Google Scholar
• Guido C, Menezes DW, Lin Z, Pestell RG, Howell A, Zimmers TA, Casimiro MC, Aquila S, Ando' S, Martinez-Outschoorn UE, et al. Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth. Oncotarget 2012; 3:798-810; PMID:22878233
   PubMed Web of Science ®Google Scholar
• Aboussekhra A. Role of cancer-associated fibroblasts in breast cancer development and prognosis. Int J Dev Biol 2011; 55:841-9; PMID:22161840; http://dx.doi.org/10.1387/ijdb.113362aa
   PubMed Web of Science ®Google Scholar
• Molloy AP, Martin FT, Dwyer RM, Griffin TP, Murphy M, Barry FP, O'Brien T, Kerin MJ. Mesenchymal Sstem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer 2009; 124:326-32; PMID:19003962; http://dx.doi.org/10.1002/ijc.23939
   PubMed Web of Science ®Google Scholar
• Nam JS, Kang MJ, Suchar AM, Shimamura T, Kohn EA, Michalowska AM, Jordan VC, Hirohashi S, Wakefield LM. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res 2006; 66:7176-84; PMID:16849564; http://dx.doi.org/10.1158/0008-5472.CAN-06-0825
   PubMed Web of Science ®Google Scholar
• Pinilla S, Alt E, Abdul Khalek FJ, Jotzu C, Muehlberg F, Beckmann C, Song YH. Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett 2009; 284:80-5; PMID:19427114; http://dx.doi.org/10.1016/j.canlet.2009.04.013
   PubMed Web of Science ®Google Scholar
• Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008; 267:271-85; PMID:18439751; http://dx.doi.org/10.1016/j.canlet.2008.03.018
   PubMed Web of Science ®Google Scholar
• Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, Lang SA. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 2011; 10:2157-67; PMID:21885862; http://dx.doi.org/10.1158/1535-7163.MCT-11-0312
   PubMed Web of Science ®Google Scholar
• Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010; 70:4151-62; PMID:20460524; http://dx.doi.org/10.1158/0008-5472.CAN-09-4479
   PubMed Web of Science ®Google Scholar
• Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011; 104:75-82; PMID:21119661; http://dx.doi.org/10.1038/sj.bjc.6606016
   PubMed Web of Science ®Google Scholar
• Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008; 5:e19; PMID:18232728; http://dx.doi.org/10.1371/journal.pmed.0050019
   PubMed Web of Science ®Google Scholar
• Mattila MM, Harkonen PL. Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. Cytokine Growth Factor Rev 2007; 18:257-66; PMID:17512240; http://dx.doi.org/10.1016/j.cytogfr.2007.04.010
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006; 12:6652-62; PMID:17121884
   PubMed Web of Science ®Google Scholar
• Renhowe PA, Pecchi S, Shafer CM, Machajewski TD, Jazan EM, Taylor C, Antonios-McCrea W, McBride CM, Frazier K, Wiesmann M, et al. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. J Med Chem 2009; 52:278-92; PMID:19113866; http://dx.doi.org/10.1021/jm800790t
   PubMed Web of Science ®Google Scholar
• Ehnman M, Östman A. Therapeutic targeting of platelet-derived growth factor receptors in solid tumors. Expert Opin Investig Drugs 2014; 23:211-26; PMID:24206431; http://dx.doi.org/10.1517/13543784.2014.847086
   PubMed Web of Science ®Google Scholar
• Fearon AE, Gould CR, Grose RP. FGFR signalling in women's cancers. Int J Biochem Cell Biol 2013; 45:2832-42; PMID:24148254; http://dx.doi.org/10.1016/j.biocel.2013.09.017
   PubMed Web of Science ®Google Scholar
• Chin YR, Toker A. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell Signal 2009; 21:470-6; PMID:19110052; http://dx.doi.org/10.1016/j.cellsig.2008.11.015
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-9; PMID:19249681; http://dx.doi.org/10.1016/j.ccr.2009.01.021
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31; PMID:19249680; http://dx.doi.org/10.1016/j.ccr.2009.01.027
   PubMed Web of Science ®Google Scholar
• Huynh H, Chow PK, Tai WM, Choo SP, Chung AY, Ong HS, Linnartz R, Shi MM. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol 2012; 56:595-601; PMID:22027573; http://dx.doi.org/10.1016/j.jhep.2011.09.017
   PubMed Web of Science ®Google Scholar
• Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth–bystanders turning into key players. Curr Opin Genet Dev 2009; 19:67-73; PMID:19211240; http://dx.doi.org/10.1016/j.gde.2009.01.003
   PubMed Web of Science ®Google Scholar
• Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS.Med 2008; 5:e19; PMID:18232728; http://dx.doi.org/10.1371/journal.pmed.0050019
   PubMed Web of Science ®Google Scholar
• Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C, Oei Y, et al. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005; 11:5281-91; PMID:16033847
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-67; PMID:21633166; http://dx.doi.org/10.1172/JCI45014
   PubMed Web of Science ®Google Scholar
• Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, Molchansky A, Milliman JN, Whitaker-Menezes D, Sotgia F, et al. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol 2012; 181:278-93; PMID:22698676; http://dx.doi.org/10.1016/j.ajpath.2012.03.017
   PubMed Web of Science ®Google Scholar
• Capparelli C, Chiavarina B, Whitaker-Menezes D, Pestell TG, Pestell RG, Hulit J, Andò S, Howell A, Martinez-Outschoorn UE, Sotgia F, et al. CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle 2012; 11:3599-610; PMID:22935696; http://dx.doi.org/10.4161/cc.21884
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Rapalogs in cancer prevention: anti-aging or anticancer? Cancer Biol Ther 2012; 13:1349-54; PMID:23151465; http://dx.doi.org/10.4161/cbt.22859
   PubMed Web of Science ®Google Scholar
• Andre F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 2013; 19:3693-702; PMID:23658459; http://dx.doi.org/10.1158/1078-0432.CCR-13-0190
   PubMed Web of Science ®Google Scholar
• Issa A, Gill JW, Heideman MR, Sahin O, Wiemann S, Dey JH, Hynes NE. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res 2013; 15:R8; PMID:23343422; http://dx.doi.org/10.1186/bcr3379
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Rosenfeld SV, Blagosklonny MV. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 2011; 10:4230-6; PMID:22107964; http://dx.doi.org/10.4161/cc.10.24.18486
   PubMed Web of Science ®Google Scholar
• Sadlonova A, Novak Z, Johnson MR, Bowe DB, Gault SR, Page GP, Thottassery JV, Welch DR, Frost AR. Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Res 2005; 7:R46-R59; PMID:15642169; http://dx.doi.org/10.1186/bcr949
   PubMed Web of Science ®Google Scholar
• Liu H, Zang C, Fenner MH, Liu D, Possinger K, Koeffler HP, Elstner E. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. Blood 2006; 107: 3683-92; PMID:16403907; http://dx.doi.org/10.1182/blood-2005-05-2103
   PubMed Web of Science ®Google Scholar